2023
High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia
Paudel K, Gupta S, Gautam K, Wickersham J, Khati A, Azwa I, Ha T, Shrestha R. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia. Journal Of Community Health 2023, 48: 513-521. PMID: 36732459, PMCID: PMC10200758, DOI: 10.1007/s10900-023-01195-8.Peer-Reviewed Original ResearchConceptsLAI-PrEPHIV preventionInjectable pre-exposure prophylaxisLong-term side effectsPre-exposure prophylaxisOnline cross-sectional surveyCross-sectional surveyInjectable cabotegravirInjectable PrEPMalaysian MSMPrEP modalitiesOral PrEPHIV testingMiddle-income countriesOral pillsPrior historySide effectsRecent approvalPrEP optionsStudy participantsMSMPrEPNationwide surveyConvenience samplingNationwide sample
2022
COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey
Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, Aoun-Barakat L, Virata M, Olivares M, Wickersham JA. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines 2022, 10: 424. PMID: 35335054, PMCID: PMC8949562, DOI: 10.3390/vaccines10030424.Peer-Reviewed Original ResearchCOVID-19 vaccine hesitancyVaccine hesitancySevere COVID-19 diseaseMean timeSample of PWHCells/mm3COVID-19 historyVaccine-related concernsGreater vaccine hesitancyCOVID-19 vaccineCOVID-19COVID-19 diseaseLower vaccine hesitancyCross-sectional online surveyCD4 countAssociated FactorsSide effectsHIVKey populationsPWHMultivariate linear regressionVaccineCOVID-19 epidemicHesitancyMost participants
2020
Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs
Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal Of Substance Use And Addiction Treatment 2020, 117: 108058. PMID: 32811633, PMCID: PMC7438607, DOI: 10.1016/j.jsat.2020.108058.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisInjectable pre-exposure prophylaxisLAI-PrEPOral pre-exposure prophylaxisLong-term side effectsSelf-reported HIV risk behaviorsBangkok Tenofovir StudyEvidence-based HIVHigh-risk PWUDImportant key populationHIV-negative peopleOpioid use disorderHIV risk behaviorsHIV prevention effortsAddiction treatment programsDaily PrEPOral PrEPAdherence challengesIndependent correlatesFemale sexClinical trialsHIV preventionIndependent factorsSide effectsUse disorders
2017
Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users
Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS And Behavior 2017, 22: 1228-1238. PMID: 28695388, PMCID: PMC5762432, DOI: 10.1007/s10461-017-1851-1.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSex-related risk behaviorsHigh-risk drug usersAcceptability of PrEPHigh-risk PWUDPrimary HIV preventionHIV prevention approachesDrug treatment settingsKey risk populationsHIV-negative PWUDHigh acceptabilityHIV clinicPrEP acceptabilityHIV testingPrEP uptakeMethadone clinicsHIV preventionRisk populationsSide effectsTreatment settingsDrug usersPrEP attributesRisk behaviorsPrEPUnderserved populations